MAPK7 and melanoma: Unlike BRAFV600E-driven melanoma cells, shRNA-mediated silencing of ERK5 in NRASQ61L/K driven melanoma had no effect on its own; however, a combination of MEKi and shERK5 decreased cell viability and this result was confirmed with the MEK5 inhibitor, BIX02188.